WORK EXPERIENCE

2017 – present Co-founder of the venture capital fund «TealTech Capital», focused on investing in «organisations of the future» (in partnership with VkusVill and Agama Group).

2011 – present Head of the Department of Innovative Pharmaceuticals, Medical Devices and Biotechnology at the Moscow Institute of Physics and Technology (MIPT).

1995 – present Chairman of the Board of Directors of the Non-Commercial Partnership «ChemRar High-Tech Centre» (HTC «ChemRar»).

PUBLIC AND PROFESSIONAL ACTIVITIES

2023 – present Chairman of the MIPT Alumni Council.

2020 – present Member of the Board of Trustees of the Phystech XXI School Cluster and the P.L. Kapitsa Phystech-Lyceum (autonomous non-profit educational organisation).

2020 – present Leader of the Expert Group on «New Types of Entrepreneurial Activity Based on the Introduction of Advanced Technologies» (within the National Technology Initiative).

2016 – present Member of the Expert Council for the Development of Biotechnology, Pharmaceuticals and the Medical Industry under the Committee on Industry of the State Duma of the Russian Federation.

2013 – present Member of the Governing Board of the «Phystech-Union» Association.

2012 – present Member of the Supervisory Board of the Moscow Institute of Physics and Technology (MIPT). Honorary Professor of MIPT.

2010 – present Member of the Council of the Phystech Schools Development Foundation.

2010 – present Member of the Supervisory Board of the Severny Biopharmaceutical Cluster (BFC «Severny»).

One of the initiators of the establishment of the Severny Biopharmaceutical Cluster on the basis of the Moscow Institute of Physics and Technology (MIPT).

2015 – 2025 Leader of the Working Group for the development and implementation of the «NeuroNet» Roadmap under the National Technology Initiative (NTI) at the Presidium of the Council for Economic Modernisation and Innovative Development under the President of the Russian Federation.

2023 – present Scientific Consultant at CDRI LLC.

2003 – 2023 Chief Executive Officer of the Chemical Diversity Research Institute LLC (over 300 employees). Managed innovative projects, conducted in-house and contract research and development (R&D) in the field of preclinical and clinical studies of innovative medicinal products for domestic and international companies, as well as the development of laboratory and pilot-scale production protocols for synthetic and biotechnological pharmaceuticals.

1999 – 2003 Head of the Organic Synthesis Department within the ChemRar Group divisions. Synthesis of biologically active compounds for high-throughput screening (HTS).

1995 – 1999 Senior Research Fellow at the Laboratory of Immunomodulators, Research Institute of Gerontology under the Ministry of Health of the Russian Federation. Manufacture of intravenous immunoglobulin (IVIG).

2009 – present ChemRar Ventures LLC, Chief Executive Officer. Venture capital investments in projects developing innovative medicinal products.

2004 – 2009 Kontur LLC, Deputy Chief Executive Officer. Managed venture capital investment in a project developing a novel thermal insulation material technology.

2001 – 2004 Liding Financial and Investment Company CJSC, Head of the Direct Investment Department. Venture capital investments in the fields of biotechnology, nanotechnology and advanced materials.

2000 – 2001 IBG NIKoil, Venture Business Directorate, Director. Venture capital investments.

1999 – 2000 IBG NIKoil, Director for Internal Cost Accounting. Implementation of a management information system.

1998 – 1999 Mosbusinessbank, Financial Department, Head of Division. Implementation of a management information system.

1995 – 1998 Mosbusinessbank, Automation and Settlements Department, Head of Division. Development of the bank’s IT strategy.

1992 – 1995 EDI-Press Agency, Chief Executive Officer. Development of banking software and publishing activities.

Master’s degree in Finance at Stockholm University in 2005.

More than 12 years of corporate governance experience in the chemical and pharmaceutical industry. Monitoring of financial transactions and strategic partnership issues.

Since 1998, Irina has held key positions within the ChemRar Group in areas related to marketing, sales and business development in international drug research and development (R&D) projects.

In 2009, Irina was appointed Chief Executive Officer of Viriom LLC, where she led a project to develop, register and bring to market a next-generation medicinal product for the treatment of HIV infection.

From 2017 to 2023, Irina headed the ChemRar Research Institute – a leading contract research organisation (CRO) for the development of innovative medicinal products in Russia.

From 2021 to 2024, Irina served as Chief Executive Officer of Cromis LLC, a joint venture between the Russian Direct Investment Fund (RDIF) and ChemRar Group, focused on the development and market launch of Avifavir, the first medicinal product in Russia and worldwide for the treatment of coronavirus infection. Irina is a member of the Board of Directors of ChemRar Group, overseeing the development of the group’s export business.

From 2024 to the present, Irina has served as Head of International Cooperation for the Development of Innovative Medicinal Products.